hypermutation

(redirected from Somatic hypermutation)
Also found in: Acronyms, Wikipedia.

hypermutation

(hī'pĕr-myū-tā'shŭn),
A process whereby heavy and light chain genes of the antibody molecule are mutated at a high rate, leading to diversity in the antibody repertoire.
References in periodicals archive ?
Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004;103:1869-75.
Deficiency of somatic hypermutation of the antibody light chain is associated with increased frequency of severe respiratory tract infection in common variable immunodeficiency.
Knockout mice for MSK1/2 and S133A knockin mice for CREB will be utilized for both in vivo and ex vivo studies of CSR and somatic hypermutation.
The SHM-XEL platform, which couples fully human antibody libraries with in-vitro somatic hypermutation in mammalian cells to generate high affinity antibodies, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.
(3,5-9) Furthermore, BCL6 mutations occur in diffuse large B-cell lymphomas and other types of germinal center or postgerminal center-derived lymphomas; this has been suggested as a mechanism for aberrant BCL6 expression, although the presence of similar changes following somatic hypermutation in benign B cells complicates the interpretation of this finding.
The contributors review research findings on protein tyrosine phosphatases, interleukin-21, class switch recombination, thymus organogenesis, somatic hypermutation, and T follicular helper cells.
Study of somatic hypermutation of the immunoglobulin heavy chain variable region (IGHV) genes provides valuable insights into the origin of B-cell lymphoma.
The SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.
Somatic hypermutation is, in part, responsible, for affinity maturation during an immune response.
Other topics include antibody somatic hypermutation, the function of site-specific histone acetylation, lipid A modification systems in gram-negative bacteria, and signaling pathways downstream of pattern-recognition receptors.
The company's SHM-XEL antibody platform is designed to couple fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates and replicates key features of the human immune system and overcomes limitations of prior antibody technologies.